NCT01869400 (NIS-OvaYond) is a clinical trial in Recurrent Ovarian Cancer, sponsored by PharmaMar, Spain.

Who is sponsoring NCT01869400?

NCT01869400 is sponsored by PharmaMar, Spain.

What condition does NCT01869400 study?

NCT01869400 studies Recurrent Ovarian Cancer.

Is NCT01869400 still recruiting?

NCT01869400 is currently completed. Last updated 4 April 2018.

Last reviewed 2018-04-04 · How we verify

NCT01869400: NIS-OvaYond

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational, Multicenter, Open-label Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

Completed Last updated 4 April 2018

What this trial tests

trial in Recurrent Ovarian Cancer in 83 participants. Completed in 1 February 2017.

Timeline

1 April 2013

Primary endpoint
1 December 2016

1 February 2017

Quick facts

Lead sponsor	PharmaMar, Spain
Status	Completed
Study type	OBSERVATIONAL
Enrollment	83
Start date	1 April 2013
Primary completion	1 December 2016
Estimated completion	1 February 2017
Sites	2 locations across Germany

Conditions studied

Recurrent Ovarian Cancer — all drugs for Recurrent Ovarian Cancer →

Sponsor

PharmaMar, Spain

Who can join

18 and older, female only, with Recurrent Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

safety and tolerability data of the study therapy
Time frame: during Yondelis-PLD-therapy
Number of patients with adverse events

Sponsor's own description

Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined patient groups, which are not representative for the whole patient population. Especially elderly patients and patients with co-morbidities are underrepresented in clinical trials. This non-interventional study will examine the efficiency and toxicity of the Yondelis® + PLD combination therapy in a general patient population to evaluate if the data collected in the clinical trials can be assigned to a general patient population.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, et al · · 2018 · cited 6× · PMID 29623421 · DOI 10.1007/s00432-018-2637-1
Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.
Li C, Qiao S, Kang M, Gao X, et al · · 2023 · cited 3× · PMID 38186978

Verify or expand the search:

Other recruiting trials for Recurrent Ovarian Cancer

Currently open trials in the same condition.

NCT06769425 — HS-10502 Combination Treatment in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT07495384 — Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro · NA · recruiting
NCT06560112 — An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer · Phase 2 · recruiting
NCT05610735 — Combination Therapy for Recurrent Ovarian Cancer · Phase 1, PHASE2 · recruiting
NCT06107868 — Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer · Phase 1 · active not recruiting

Other PharmaMar, Spain trials

Trials by the same sponsor.

NCT02367924 — Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01869400 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PharmaMar, Spain
Last refreshed: 4 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01869400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing